Empowered Patient Podcast

Paul Kohlhaas, Founder, Molecule is passionate about creating a network for the decentralization of the process of researching new molecules and developing new molecular compounds using blockchain to track and reward all those who participate. With the current pharma innovation crisis and rising costs of drug development, new methods are needed to break down silos and overcome challenges of drug resistance and treating rare diseases.

@molecule_to

Molecule.to

Download the transcript here.

Paul Kohlhaas, Founder, Molecule is passionate about creating a network for the decentralization of the process of researching new molecules and developing new molecular compounds using blockchain to track and reward all those who participate. With the current pharma innovation crisis and rising costs of drug development, new methods are needed to break down silos and overcome challenges of drug resistance and treating rare diseases.

@molecule_to

Molecule.to

Listen to the podcast here.

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland. She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors. Download the transcript. Listen to the podcast here.

@TiburioT

#neuroendocrine #pituitaryadenoma #chiefmedicalofficer #raredisease #NFPA

Tiburio Therapeutics

Dr. Nerissa Kreher, Chief Medical Officer, Tiburio discusses the company's lead asset, TBR-760 as a novel treatment option for patients with non-functioning pituitary adenomas (NFPA), which are rare neuroendocrine tumors located in the pituitary gland. She also speaks about the challenges facing patients even after surgical or radiation treatments for these pituitary tumors.

@TiburioT

#neuroendocrine #pituitaryadenoma #chiefmedicalofficer #raredisease #NFPA

Tiburio Therapeutics

Download the PDF file of the interview here.

Venkat Nelabhotla, Chief Executive Officer, Vyome Therapeutics discusses the growing problem of antimicrobial resistance in medicine and how Vyome is working to tackle resistant dermatological conditions using their understanding of the skin microbiome.

Focusing first on acne, Vyome is developing VB-1953, a topical gel capable of killing resistant strains of P. acnes to help deliver solutions to the more than 10 million patients in the US, and more world-wide, with antibiotic resistant acne.

@vyometx

Vyome Therapeutics

Download the transcript.

Listen to the podcast here.

Venkat Nelabhotla, Chief Executive Officer, Vyome Therapeutics discusses the growing problem of antimicrobial resistance in medicine and how Vyome is working to tackle resistant dermatological conditions using their understanding of the skin microbiome. Focusing first on acne, Vyome is developing VB-1953, a topical gel capable of killing resistant strains of P. acnes to help deliver solutions to the more than 10 million patients in the US, and more world-wide, with antibiotic resistant acne.

@vyometx

Vyome Therapeutics

Dr. Greg van Wyk, CMO and recently appointed CEO, Noxopharm talks about the Company's current milestones and upcoming news related to its lead clinical drug candidate, Veyonda, a chemotherapy and radiation enhancer that is being studied in men with late stage metastatic prostate cancer and that may have broad applicability in other cancer types. Greg notes the explosion of mergers and acquisitions particularly in the oncology space due to increasing interest in combining one or more molecules in treatments.

Read the transcript here and listen to the podcast with this link.

Dr. Greg van Wyk, CMO and recently appointed CEO, Noxopharm talks about the Company's current milestones and upcoming news related to its lead clinical drug candidate, Veyonda, a chemotherapy and radiation enhancer that is being studied in men with late stage metastatic prostate cancer and that may have broad applicability in other cancer types. Greg notes the explosion of mergers and acquisitions particularly in the oncology space due to increasing interest in combining one or more molecules in treatments.

@Noxopharm

#prostatecancer #cancer #chemotherapy #radiation

Noxopharm

Terri Wingham, Founder, A Fresh Chapter was diagnosed with an aggressive form of cancer when she was in her 30's. As a result she founded A Fresh Chapter, giving cancer survivors and caregivers an opportunity to travel to foreign and US destinations to get outside of their comfort zone and discover new possibilities, community and purpose. These odysseys are supplemented by online resources and financial underwriting from corporate sponsors including Eli Lilly.

@afreshchapter

#cancer

A Fresh Chapter

Preston Klassen, MD Chief Medical Officer, Arena Pharmaceuticals talks about the challenges of treating Inflammatory Bowel Diseases (IBD) and Arena's developmental therapies for ulcerative colitis and Crohn's disease. We also talk about the development of a treatment for related gastrointestinal pain with a non-opioid alternative.

#Arena #Ulcerativecolitis #GI #IBD #crohns

@ArenaPharm

Arena Pharmaceuticals

Arena Pharmaceuticals